Top

BY Scott Merville

Combining two immunotherapies caused tumor rejection in mouse models of pancreatic cancer and provided long-term immune memory that prevented recurrence when tumors were reimplanted in responders months later, researchers MD Anderson report today in Gastroenterology.

The promising combination -- an anti-PD-1 immune checkpoint inhibitor and an antibody that activates the immune-stimulating molecule OX40 – merits further development...

PD-1 checkpoint inhibitor with an antibody that turns on immune-stimulating OX40

BY Clayton Boldt, Ph.D.

In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...

BY Clayton Boldt, Ph.D.

Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...

Raghu Kalluri, M.D., Ph.D.

BY Meagan Raeke

“Trainees at the Ph.D. and postdoctoral level are leaving the academic research track at alarming rates, and disproportionately if they’re...

BY Scott Merville

Surveying the landscape of T cell presence and activity across the lungs of patients treated for localized non-small cell lung cancer, researchers...

BY Lany Kimmons

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of ALCL that was first reported in 1996. The U.S....

BY Kellie Bramlet

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a type of cancer treatment in which surgeons apply heated chemotherapy...

BY Meagan Raeke

While U.S. cervical cancer rates have fallen by 70% since the 1950s thanks to the Pap test and national screening programs, the disease...

BY Clayton Boldt, Ph.D.

Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...